Cargando…
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Rivaroxaban (Xarelto(®)) is a member of a new class of oral, direct (antithrombinindependent) factor Xa inhibitors, which restrict thrombin generation both in vitro and in vivo. After oral administration the absorption is near 100%, the bioavailability is near 80%, and the elimination half-life is 5...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597756/ https://www.ncbi.nlm.nih.gov/pubmed/19066002 |